Raloxifene News and Research

RSS

Raloxifene is an oral selective estrogen receptor modulator (SERM) that has oestrogenic actions on bone and anti-oestrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.

Systematic estimation of breast cancer risk appears justified in postmenopausal women

Screening for breast cancer risk in all postmenopausal women, using a combination of risk factors and breast density, can identify women at high risk of disease, according to systematic literature reviews and meta-analyses reported in the March 10 online issue of the Journal of the National Cancer Institute.

11 Mar 2009

Eli Lilly granted temporary restraining order to halt launch of generic Raloxifene

Eli Lilly and Company has issued the following statement after being granted a temporary restraining order to halt the launch of a generic version of Evista (raloxifene HCl tablets) by Teva Pharmaceuticals.

11 Mar 2009

Breast cancer common among women with family history but without BRCA1 or BRCA2 mutation

New data presented at the American Association for Cancer Research's Seventh Annual International Frontiers in Cancer Prevention Research meeting outlines new data, which assesses breast cancer risk among women with a strong family history of breast cancer, but without a BRCA1 or BRCA2 mutation.

17 Nov 2008

Gail model no better than coin flip in predicting risk of breast cancer

A statistical model commonly used to predict the risk of breast cancer in women was not accurate when used to evaluate women with atypical hyperplasia, according to a new Mayo Clinic study published in the Oct. 14, 2008, issue of the Journal of Clinical Oncology.

6 Nov 2008

Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women

New analysis of a drug approved for osteoporosis prevention and treatment has provided definitive evidence that the medication is also effective as a breast cancer preventative for certain cancers.

11 Jun 2008

Reduced incidence of invasive breast cancer with Raloxifene among women at increased coronary risk

Women who took raloxifene were less likely to develop invasive estrogen-receptor (ER) positive breast cancer compared with women who did not, according to data from a randomized controlled trial published online June 10 in the Journal of the National Cancer Institute. The drug did not reduce the risk of non-invasive cancer or invasive ER-negative cancers.

11 Jun 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008

The effect of Raloxifene treatment in postmenopausal women with chronic kidney disease

The osteoporosis drug raloxifene increases bone mineral density and reduces the risk of vertebral fractures among postmenopausal women with mild to moderate chronic kidney disease (CKD), according to a study appearing in the July 2008 issue of the Journal of the American Society Nephrology.

10 Apr 2008

Value of drugs for pre-osteoporosis exaggerated

A series of recent scientific publications have exaggerated the benefits and underplayed the harms of drugs to treat pre-osteoporosis or "osteopenia" potentially encouraging treatment in millions of low risk women, warn experts in this week's BMJ.

21 Jan 2008

Effectiveness and risks of six bisphosphonates for osteoporosis

Many medications reduce the risk of bone fractures in people with osteoporosis, but the most commonly used drugs - bisphosphonates - have not been proven more effective than alternatives, according to a new report funded by the Agency for Healthcare Research and Quality (AHRQ), part of the U.S. Department of Health and Human Services.

18 Dec 2007

Evista (raloxifene hydrochloride) approved for breast cancer

The U.S. Food and Drug Administration today approved Evista (raloxifene hydrochloride) for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

17 Sep 2007

Breast cancer prevention practices vary across Canada

Breast cancer preventive practices for Canadian women carrying the cancer gene vary across the country, says University of Toronto research, and many women are not taking advantage of the options available.

16 Aug 2007

Sex and gender in cardiovascular-renal physiology and pathophysiology

Gender influences the prevalence and progression rate of many renal diseases, such as polycystic kidney disease (PKD).

9 Aug 2007

FDA panel will help decide fate of drug Evista for preventing breast cancer

Before the osteoporosis drug Evista is approved for breast cancer in the U.S. the Food and Drug Administration (FDA) will take the advice of an advisory panel.

23 Jul 2007

Health care professionals should focus on women's lifetime heart disease risk

The 2007 Guidelines for Preventing Cardiovascular Disease in Women -- published today in a special women's health issue of Circulation: Journal of the American Heart Association -- also include new directions for using aspirin, hormone therapy and vitamin and mineral supplements in heart disease and stroke prevention in women.

20 Feb 2007

Raloxifene News and Research

Systematic estimation of breast cancer risk appears justified in postmenopausal women

Eli Lilly granted temporary restraining order to halt launch of generic Raloxifene

Breast cancer common among women with family history but without BRCA1 or BRCA2 mutation

Gail model no better than coin flip in predicting risk of breast cancer

Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women

Reduced incidence of invasive breast cancer with Raloxifene among women at increased coronary risk

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

The effect of Raloxifene treatment in postmenopausal women with chronic kidney disease

Value of drugs for pre-osteoporosis exaggerated

Effectiveness and risks of six bisphosphonates for osteoporosis

Evista (raloxifene hydrochloride) approved for breast cancer

Breast cancer prevention practices vary across Canada

Sex and gender in cardiovascular-renal physiology and pathophysiology

FDA panel will help decide fate of drug Evista for preventing breast cancer

Health care professionals should focus on women's lifetime heart disease risk

An aspirin a day keeps heart disease away

Updated guidelines provide definitive answers on HRT, aspirin, supplements

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

Raloxifene reduces breast cancer risk in postmenopausal women

Hormonal treatments reduce risk of cancer returning

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News